NASDAQ:KITE

(KITE) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$179.79
0.00 (0.00 %)
(As of 10/19/2017)
Add
Today's Range
$179.79
$179.79
50-Day Range N/A
52-Week Range
$39.82
$179.99
VolumeN/A
Average Volume1.65 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive KITE News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.


(KITE) logo

About (KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











(KITE) (NASDAQ:KITE) Frequently Asked Questions

What stocks does MarketBeat like better than (KITE)?

Wall Street analysts have given (KITE) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but (KITE) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) posted its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $5.74 million. The company's revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.54) earnings per share.
View (KITE)'s earnings history
.

Who are (KITE)'s key executives?

(KITE)'s management team includes the following people:
  • Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, Founder
  • Paul L. Jenkinson, Chief Financial Officer
  • Cynthia M. Butitta, Chief Operating Officer
  • David Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical Officer
  • Helen S. Kim, Executive Vice President - Business Development
  • Timothy L. Moore, Executive Vice President - Technical Operations
  • Christine Cassiano, Senior Vice President - Corporate Communications and Investor Relations
  • , Bio & Compensation - 
  • Jian Irish Ph.D., Senior Vice President - Supply Chain
  • , Bio & Compensation - 
  • Jeffrey Wiezorek M.D., Senior Vice President - Clinical Development
  • Shawn Cline Tomasello, Chief Commercial Officer

What other stocks do shareholders of (KITE) own?

What is (KITE)'s stock symbol?

(KITE) trades on the NASDAQ under the ticker symbol "KITE."

What is (KITE)'s stock price today?

One share of KITE stock can currently be purchased for approximately $179.79.

What is (KITE)'s official website?

The official website for (KITE) is www.kitepharma.com.

Where are (KITE)'s headquarters?

(KITE) is headquartered at 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States.

How can I contact (KITE)?

(KITE)'s mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999.


This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.